Anthracycline News and Research

RSS
Anthracycline is a type of antibiotic that comes from certain types of Streptomyces bacteria. Anthracyclines are used to treat many types of cancer. Anthracyclines damage the DNA in cancer cells, causing them to die. Daunorubicin, doxorubicin, and epirubicin are anthracyclines.
Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

Genentech submits BLA for trastuzumab-DM1 in advanced HER2-positive breast cancer

CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL

CTI submits expanded PIP to EMEA for pixantrone MAA for relapsed or refractory, aggressive NHL

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Eribulin mesylate drug may help extend lives of women with advanced breast cancer

Eribulin mesylate drug may help extend lives of women with advanced breast cancer

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Genta presents tesetaxel dose-ranging trial results at ASCO 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

FDA grants priority review status to Eisai's eribulin NDA

FDA grants priority review status to Eisai's eribulin NDA

EMEND indication helps women prevent CINV

EMEND indication helps women prevent CINV

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Data evaluating use of nab-paclitaxel for treatment of pancreatic cancer to be presented at ASCO 2010

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Phase III PRIMA study data of Rituxan to be featured at 46th ASCO

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech to present new data for targeted cancer medicines at 46th ASCO